Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1220932 | 0.83 | RAB9A (0.47) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL541998 | 0.81 | MAPT (0.56) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1219816 | 0.81 | NOTUM (0.47) | RAB9ANPC1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL1221372 | 0.81 | RAB9A (0.51) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1219704 | 0.81 | RAB9A (0.45) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1221320 | 0.79 | CYP19A1 (0.55) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1220844 | 0.79 | L3MBTL1 (0.53) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1221306 | 0.78 | MAPT (0.66) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1221909 | 0.78 | L3MBTL1 (0.59) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL1220628 | 0.77 | L3MBTL1 (0.43) | RAB9ANPC1L3MBTL1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | RAB9A 2101/4885NPC1 228/4885L3MBTL1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.